{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:05:25Z","timestamp":1792321525494,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cgh.2013.12.016","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T10:46:54Z","timestamp":1387536414000},"page":"1550-1555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome"],"prefix":"10.1016","volume":"12","author":[{"given":"Raj","family":"Vuppalanchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavender","family":"Gotur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej S.","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiezhun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2013.12.016_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.12.016_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.12.016_bib3","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/FPC.0b013e3283589a76","article-title":"Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs","volume":"22","author":"Urban","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cgh.2013.12.016_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.12.016_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.12.016_bib6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.12.016_bib7","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in\u00a0vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cgh.2013.12.016_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.pharmtox.47.120505.105150","article-title":"Idiosyncratic drug reactions: current understanding","volume":"47","author":"Uetrecht","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cgh.2013.12.016_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.26295","article-title":"Avoiding idiosyncratic DILI: two is better than one","volume":"58","author":"Kaplowitz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.12.016_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/mp8001864","article-title":"The use of drug metabolism for prediction of intestinal permeability (dagger)","volume":"6","author":"Chen","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cgh.2013.12.016_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2013.12.016_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jps.23359","article-title":"The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development","volume":"102","author":"Benet","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.cgh.2013.12.016_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11095-007-9523-x","article-title":"The use of BDDCS in classifying the permeability of marketed drugs","volume":"25","author":"Benet","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.cgh.2013.12.016_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.12.016_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cgh.2013.12.016_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2013.12.016_bib17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.12.016_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/clpt.2010.355","article-title":"A\u00a0fresh look at the mechanism of isoniazid-induced hepatotoxicity","volume":"89","author":"Metushi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2013.12.016_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2012.107","article-title":"Predictive genetic testing for drug-induced liver injury: considerations of clinical utility","volume":"92","author":"Alfirevic","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2013.12.016_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-7843.2009.00498.x","article-title":"Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System","volume":"106","author":"Benet","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cgh.2013.12.016_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.cgh.2013.12.016_bib22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2013.12.016_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1749-6632.1993.tb35929.x","article-title":"Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis","volume":"685","author":"Beaune","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cgh.2013.12.016_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.1996.tb01652.x","article-title":"Anti-cytochrome P450 autoantibodies in drug-induced disease","volume":"60","author":"Beaune","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.cgh.2013.12.016_bib25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513019629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513019629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:13:56Z","timestamp":1761542036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356513019629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1542356513019629"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2013.12.016","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2013.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}